A high-profile court case has thrust the legalities of compounding medicines in South Africa into the spotlight. Behind the immediate legal issues, hide a series of unresolved questions about how we should ensure that compounded medicines used in South Africa are safe, argue Professor Renier Coetzee and Lara van Niekerk.
In part 3 of a Spotlight special series on the role of new weight loss medicines like Ozempic in South Africa, we ask what these breakthrough jabs might mean for people living with HIV in the country. There is some tantalising early research on potential benefits, but also many uncertainties. Catherine Tomlinson reports.
In South Africa, access to weight loss medicines like Ozempic and Mounjaro remains limited to those who can shell out a few thousand Rand a month. In the second article of a Spotlight special series, Catherine Tomlinson looks at the medical need for these medicines in the country and what it would take for government to provide them in the public sector.
Sales of weight loss medicines like Ozempic and Mounjaro have sky-rocketed in South Africa in recent years, although they remain too expensive for most people who might benefit from the jabs. In the first article of this Spotlight special series, Catherine Tomlinson tracks their remarkable rise and assesses when they will become more widely available here.
The obesity epidemic will hit South Africa hard on top of our high HIV burden, but advocate researcher and scientist Dr Nomathemba Chandiwana says she is ready to fight back harder. She speaks to Ufrieda Ho about her journey from working in state hospitals to transitioning into obesity medicine, and her move to Cape Town.
Health workers have long relied on Body Mass Index (BMI) as a way to measure whether people are within a healthy weight range. Now, a collection of top researchers have made the case for a new way to understand and diagnose obesity. In part two of this special Spotlight series, we take a look at what this new framing might mean for South Africa.
Authors of a recent Lancet report argue that obesity should not just be seen as a risk factor for other diseases – but in some cases, should be seen as a disease itself. The position could change how we treat obesity globally. In the first of this two-part Spotlight series, Jesse Copelyn breaks down the debate around the issue, and its implications for health policy.
The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, access to these medicines remain limited in South Africa. Catherine Tomlinson asks which of the GLP-1 agonists are available here and at what price.
Obesity is a public health crisis in South Africa, similar to HIV in the late 1990s, Dr Nomathemba Chandiwana tells Spotlight on the sidelines of the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. She also presented research that found lifestyle behaviour changes had a limited effect on reversing weight gain in people living with HIV.
Non-communicable diseases are killing more and more people in South Africa yet the government missed out on raising a total of more than R15 billion for prevention efforts, argues Dr Evelyn Thsehla.
2023 was a busy year for healthcare in South Africa. We saw several promising policy developments, landmark court cases, important pieces of legislation, and some changes in leadership. Yet, take a step back and at facility level little seems to have changed. Shortages of healthcare workers persist, corruption is still rife, budgets tight, and our health governance crisis remains as acute as ever. Marcus Low looks back at the year in health in fewer than 1 000 words.
Experts describe rising obesity rates in South Africa as an “urgent crisis”, “a tsunami” – even an “epidemic” – that is costing lives, not to mention billions of rands. Tackling the situation warrants an action plan that is as comprehensive and cogent as the problem is dire. But does the new national strategy fit the bill? Amy Green asked several local experts.
